MRNA vs TMUS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

MRNA

38.7
AI Score
VS
TMUS Wins

TMUS

41.4
AI Score

Investment Advisor Scores

MRNA

39score
Recommendation
SELL

TMUS

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA TMUS Winner
Revenue 1.85B 69.48B TMUS
Net Income -1.96B 9.20B TMUS
Net Margin -106.3% 13.2% TMUS
Operating Income -2.07B 15.65B TMUS
ROE -28.7% 16.3% TMUS
ROA -14.6% 4.3% TMUS
Total Assets 13.47B 213.10B TMUS
Cash 1.20B 5.62B TMUS
Current Ratio 3.62 0.91 MRNA
Free Cash Flow -2.86B 14.47B TMUS

Relative Price Performance (Last 90 Days)

MRNA 1M: +2.2% · 3M: +265.4% TMUS 1M: +8.4% · 3M: -6.3%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53

RSI (14): 52.5 · Price: $231.35

TMUS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 61.5 · Price: $171.03

Fundamentals Snapshot

Metric MRNA TMUS
Market Cap — —
Forward P/E -53.3 12.2
Trailing P/E — 16.6
Revenue (TTM) — —
Revenue Growth 0.3% 0.1%
Gross Margin -0.4% 0.6%
Operating Margin -0.8% 0.2%
EPS -6.98 10.37
Dividend Yield — 0.03%

Frequently Asked Questions

Based on our detailed analysis, TMUS is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.